End‑to‑End Clinical Bioanalysis for a Multi‑Center Monoclonal Antibody Study

Clinical bioanalysis of monoclonal antibodies requires robust scientific execution and strong operational control to support reliable pharmacokinetic (PK) and immunogenicity assessment. This case study describes how Aragen’s Biosafety Solutions team supported a large pharmaceutical sponsor with end‑to‑end bioanalytical services for a multi‑center Phase II/III mAb clinical study. The effort involved high sample volumes, multiple clinical sites, extended timelines, and stringent regulatory requirements, necessitating seamless coordination across bioanalysis, kitting, logistics, and sample management to ensure consistent data quality and uninterrupted clinical trial progress

The study was conducted for a large pharmaceutical client and included Phase II/ III clinical trials. A total of 168 subjects were enrolled across 11 clinical sites. The program involved 60 clinical shipments, with bioanalysis performed on 420 pharmacokinetic (PK) samples and 672 anti‑drug antibody (ADA) samples collected over the course of the study.

Complex Method Transfer Across Matrices

Transferring PK and ADA methods from preclinical (rat, monkey) matrices to human matrices while managing differences in matrix composition and maintaining assay accuracy, sensitivity, and consistency.

Long-Term Reagent Availability and Continuity

Ensuring uninterrupted availability and performance of critical reagents over extended study durations—more than 1 year for ADA studies and 6 months for PK studies.

Sustained Method Robustness Over Time

Maintaining reliable and reproducible method performance across multiple sampling time points throughout the full clinical study lifecycle.

Operational Complexity of Multi‑Center Clinical Support

Achieving standardized bioanalytical execution across 11 clinical sites, requiring consistent lab manuals, custom sample collection kits, and structured training for site personnel.

Time-Sensitive Sample Logistics

Coordinating time‑sensitive cold‑chain logistics to transport frozen clinical samples within 24 hours while preserving analyte integrity.

High-Volume Sample and Data Management

Managing large inventories of clinical samples and associated study documentation, supported by secure tracking, storage, and archiving systems.

To address these challenges, Aragen Biosafety Solutions team designed a plan to deliver integrated, end‑to‑end support across the study lifecycle:

Method Transfer & Validation

PK and ADA methods were successfully transferred to human matrices and validated in compliance with ICH M10 and FDA guidelines, ensuring consistent and regulatory‑aligned assay performance. Sample analysis was conducted using ELISA and MSD platforms, selected based on assay requirements.

Site Enablement & Standardization

Standardized laboratory manuals, customized sample collection kits, and structured site training were developed and implemented to ensure uniform sample handling and procedural consistency across all participating clinical centres.

Logistics & Cold-Chain Optimization

Time‑sensitive cold‑chain logistics were coordinated to transport frozen clinical samples within 24 hours, maintaining controlled conditions to preserve analyte integrity throughout transit.

Centralized Sample Management

Robust systems were implemented for clinical sample tracking, storage, and archiving, along with comprehensive documentation control to ensure full traceability and readiness for audits and regulatory inspections.

• Delivered reliable, reproducible PK and ADA datasets for a Phase I/III mAb clinical study involving 168 subjects across 11 clinical sites, using validated methods compliant with ICH M10 and FDA guidelines.
• Successfully analyzed PK samples (420) and ADA samples (672) using fit‑for‑purpose bioanalytical platforms, enabling robust pharmacokinetic and immunogencity evaluation across defined sampling time points.
• Generated clear and interpretable concentration–time PK profiles for individual subjects, as shown in Figure 1, demonstrating consistent assay performance throughout the study duration.
• Executed 60 time‑critical cold‑chain shipments, ensuring timely transport of frozen clinical samples and preservation of analyte integrity.
• Centralized sample inventory management and documentation control ensured full traceability, audit readiness, and regulatory‑ready bioanalytical datasets, supporting efficient clinical study execution.

Figure 1: Pharmacokinetic profiles from clinical bioanalysis. Individual subject concentration–time PK curves generated from validated assays, illustrating consistent exposure trends across clinical sampling intervals.

This study demonstrates Aragen’s capability to deliver end-to-end bioanalytical support for complex, multi-center mAb clinical program. By combining scientific rigor with operational excellence, Aragen Biosafety Solutions team ensured reliable data generation, efficient study execution, and full regulatory compliance—supporting the successful advancement of monoclonal antibody therapeutics.

End‑to‑End Bioanalytical Expertise

Advanced PK and ADA method development and validation across biologics—from peptides to monoclonal antibodies and ADCs.

Speed & Scalability

Seamless transfer of bioanalytical methods from preclinical to human matrices within 2 weeks, enabling accelerated clinical timelines.

Proven Method Library

Extensive repository of validated methods supporting 25+ biosimilars in preclinical matrices for faster study initiation.

Regulatory‑Ready & Accredited

Methods validated per ICH M10 and FDA guidelines, supported by CDSCO‑accredited clinical bioanalysis facilities, ensuring high standards of quality and compliance for global acceptance.

Submission‑Ready Data

High‑quality bioanalytical datasets aligned with DCGI requirements, supporting smooth and efficient regulatory submissions.

Contact us today. Explore how Aragen Biosafety Solutions team’s end‑to‑end bioanalytical expertise can support your monoclonal antibody clinical programs.